The clinical progression of Parkinson's disease

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 4, 2009, Pages

  Poewe, Werner ^a   Mahlknecht, Philipp ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Disease modification; Natural history; Non motor symptoms; Preclinical PD; Progression

Indexed keywords

LEVODOPA; SELEGILINE;

ARTICLE; BRADYKINESIA; COMORBIDITY; CONSENSUS; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; HUMAN; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; RIGIDITY; SYMPTOMATOLOGY; TREMOR; ANIMAL; COMPLICATION; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 72649106902     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70831-4     Document Type: Article

References (48)

1. Schrag A., and Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 (2000) 2297-2305
2. Poewe W.H., Lees A.J., and Stern G.M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36 (1986) 1528-1530
3. Müller J., Wenning G.K., Verny M., McKee A., Chaudhuri K.R., Jellinger K., et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol 58 (2001) 259-264
4. Hely M.A., Morris J.G., Reid W.G., and Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20 (2005) 190-199
5. Olanow C.W., Schapira A.H., LeWitt P.A., Kieburtz K., Sauer D., Olivieri G., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 5 (2006) 1013-1020
6. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 (1967) 427-442
7. Marttila R.J., and Rinne U.K. Disability and progression in Parkinson's disease. Acta Neurol Scand 56 (1977) 159-169
8. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 (1993) 176-183
9. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 40 (1996) 99-107
10. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59 (2002) 1541-1550
11. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 (2004) 561-566
12. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 (2004) 2498-2508
13. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69 (2007) 1480-1490
14. Schrag A., Sampaio C., Counsell N., and Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord 21 (2006) 1200-1207
15. Schrag A., Dodel R., Spottke A., Bornschein B., Siebert U., and Quinn N.P. Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord 22 (2007) 938-945
16. Fearnley J.M., and Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991) 2283-2301
17. Greffard S., Verny M., Bonnet A.M., Beinis J.Y., Gallinari C., Meaume S., et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63 (2006) 584-588
18. Maier Hoehn M.M. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl 19 (1983) 253-264
19. Müller J., Wenning G.K., Jellinger K., McKee A., Poewe W., and Litvan I. Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 55 (2000) 888-891
20. Lücking C.B., Dürr A., Bonifati V., Vaughan J., De Michele G., Gasser T., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342 (2000) 1560-1567
21. Hely M.A., Morris J.G., Traficante R., Reid W.G., O'Sullivan D.J., and Williamson P.M. The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67 (1999) 300-307
22. Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 (2002) 604-612
23. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19 (2004) 1020-1028
24. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., and Morris J.G. The Sydney multi-center study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23 (2008) 837-844
25. Louis E.D., Marder K., Cote L., Tang M., and Mayeux R. Mortality from Parkinson disease. Arch Neurol 54 (1997) 260-264
26. Ben-Shlomo Y., Churchyard A., Head J., Hurwitz B., Overstall P., Ockelford J., et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ 316 (1998) 1191-1196
27. Diem-Zangerl A., Seppi K., Wenning G.K., Trinka E., Ransmayr G., Oberaigner W., et al. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 24 (2009) 819-825
28. Beyer M.K., Herlofson K., Arsland D., and Larsen J.P. Causes of death in a community-based study of Parkinson's disease. Acta Neurol Scand 103 (2001) 7-11
29. Ross G.W., Petrovitch H., Abbott R.D., Tanner C.M., Popper J., Masaki K., et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 63 (2008) 167-173
30. Abbott R.D., Petrovitch H., White L.R., Masaki K.H., Tanner C.M., Curb J.D., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 (2001) 456-462
31. Iranzo A., Molinuevo J.L., Santamaría J., Serradell M., Marti M.J., Valldeoriola F., et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5 (2006) 572-577
32. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15 (2000) 669-677
33. Lees A.J. The Parkinson chimera. Neurology 72 7 Suppl (2009) S2-11
34. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003) 197-211
35. Factor S.A., Feustel P.J., Friedman J.H., Comella C.L., Goetz C.G., Kurlan R., et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60 (2003) 1756-1761
36. Goetz C.G., and Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 (1993) 2227-2229
37. Goetz C.G., and Stebbins G.T. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45 (1995) 669-671
38. Aarsland D., Larsen J.P., Cummins J.L., and Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56 (1999) 595-601
39. Aarsland D., Zaccai J., and Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20 (2005) 1255-1263
40. Aarsland D., Andersen K., Larsen J.P., Lolk A., and Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60 (2003) 387-392
41. Williams-Gray C.H., Foltynie T., Brayne C.E., Robbins T.W., and Barker R.A. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130 (2007) 1787-1798
42. Janvin C.C., Larsen J.P., Aarsland D., and Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 21 (2006) 1343-1349
43. Marttila R.J., Rinne U.K., Siirtola T., and Sonninen V. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 216 (1977) 147-153
44. Ebmeier K.P., Calder S.A., Crawford J.R., Stewart L., Besson J.A., and Mutch W.J. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study. Scott Med J 35 (1990) 173-175
45. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 43 (1998) 318-325
46. Montastruc J.L., Desboeuf K., Lapeyre-Mestre M., Senard J.M., Rascol O., and Brefel-Courbon C. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 16 (2001) 511-514
47. Marras C., McDermott M.P., Rochon P.A., Tanner C.M., Naglie G., Rudolph A., et al. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology 64 (2005) 87-93
48. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334 (1996) 71-76